| CDKN2C, p18
| Field |
Suggested Entry |
| Target |
CDKN2C / p18INK4c |
| Full Name |
Cyclin-dependent kinase inhibitor 2C |
| Target Class |
Endogenous CDK inhibitor; INK4-family tumor suppressor |
| Main Binding Partners |
CDK6, CDK4 |
| Primary Biology |
G1/S cell-cycle checkpoint control, CDK4/6 inhibition, RB/E2F pathway suppression, proliferation restraint |
| Cancer Relevance |
Medium-high: tumor suppressor involved in CDK4/6-RB pathway control; loss or downregulation may contribute to pituitary tumors, brain tumors, endocrine tumors, myeloma, and other cancers |
| AD Relevance |
Low-medium: indirect relevance through aberrant neuronal cell-cycle re-entry and cell-cycle dysregulation, but not a primary AD therapeutic target |
| Therapeutic Direction |
Usually restore/support p18INK4c tumor-suppressor function or compensate for its loss with CDK4/6 pathway inhibition. Direct inhibition of p18 is generally not desirable in cancer. |
|